Bioresorbable Scaffolds
- 3 December 2019
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 140 (23), 1917-1920
- https://doi.org/10.1161/circulationaha.119.043773
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Angiographic late lumen loss revisited: impact on long-term target lesion revascularizationEuropean Heart Journal, 2018
- Neoatherosclerosis 5 Years After Bioresorbable Vascular Scaffold ImplantationJournal of the American College of Cardiology, 2018
- Three-Year Outcomes With the Absorb Bioresorbable ScaffoldCirculation, 2018
- Arterial Remodeling After Bioresorbable Scaffolds and Metallic StentsJournal of the American College of Cardiology, 2017
- Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trialThe Lancet, 2016
- Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients withde novocoronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trialEuropean Heart Journal, 2016
- Very Late Scaffold ThrombosisJournal of the American College of Cardiology, 2015
- Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trialEuropean Heart Journal, 2015
- A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trialThe Lancet, 2008
- Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trialThe Lancet, 2007